Thiamine Deficiency Clinical Trial
Official title:
The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine
Verified date | August 2023 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In Part 1, subjects will be administered thiamine, thiamine with metformin, and thiamine with trimethoprim. Part 2 will expand on Part 1 and subjects will be administered thiamine and thiamine with trimethoprim. The goal is to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine (Vitamin B1).
Status | Completed |
Enrollment | 7 |
Est. completion date | August 10, 2023 |
Est. primary completion date | August 10, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male or female between the ages of 18-65 years old. 2. Eats a wide variety of food and willing to consume study diet (i.e. not on a specific diet such as Atkins, Fodmap, etc.). 3. Written informed consent obtained from the subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: 1. Subjects who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. Self-reported severe food allergies or diet restrictions (vegans, vegetarians, Atkins, Fodmap, etc.) that would prevent consumption of study diets. 3. Subjects with extreme obesity (BMI > 35). 4. Subjects who are smokers or have smoked in the past year and/or have smoked or ingested THC/marijuana in the past week, or who are unwilling to comply with a 1-week washout. 5. Subjects with any disease affecting or impairing the function of the liver, kidney or heart. 6. Subjects with moderate to severe hypertension. 7. Subjects with diabetes mellitus, hyperthyroidism, hypothyroidism, cardiovascular disease, glaucoma. 8. Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal surgery. 9. Subjects with known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory diagnostics concerning these diseases will be performed within the present study. Volunteers who are cured of past HepC infection are eligible to participate with doctor's approval letter). 10. Alcohol use on average > 2 servings/day or > 14 servings/wk (Serving size: 12oz beer/4oz wine/2oz hard liquor) or self-reported binge drinking. 11. Subjects that are on vitamin B supplements or multi-vitamins or who have taken vitamin B supplements or multi-vitamins in the past 30 days, or are not willing to comply with a 30-day washout of vitamin B supplements. 12. Subjects with possible folate deficiency. 13. Subjects taking any other clinically significant drugs as judged by the investigator. 14. Subjects with a condition, disease, or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 15. Female subjects undergoing treatment for infertility or hormone replacement therapy (Volunteers using hormonal birth control will not be excluded). 16. Subjects who have taken antimalarials in the past 60 days. 17. Participating in another research study while participating in this research study. 18. Non-English speaking 19. Subjects with abnormal laboratory results at screening as judged by the investigator or study physician. |
Country | Name | City | State |
---|---|---|---|
United States | Jean Mayer USDA Human Nutrition Research Center on Aging | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Tufts University, University of California, Davis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Concentration-Time Curve (AUC 0-72h) | Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. | As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles) | |
Primary | Assess the effects of SLC19A3 inhibitors by Cmax | In Parts 1 and 2, assess the effects of SLC19A3 inhibitors on the absorption and distribution of thiamine as measured by the change in maximum concentration (Cmax) between the combination arm(s) and single agent arm. | As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles) | |
Secondary | Investigate metabolic signatures reflecting the activity of TPP-dependent enzymes | In Parts 1 and 2, investigate metabolic signatures reflecting the activity of TPP-dependent enzymes after the administration of thiamine or a combination of the thiamine and SLC19A3 inhibitor.
Metabolic signatures are measured in blood samples by LC-MS (measurement tool). The units of measure are relative abundance, which is expressed as a percentage of the total metabolites detected. |
As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles) | |
Secondary | Determine the effect of genetic variants of thiamine transporters | The investigators will use Sanger Sequencing of two thiamine transporters (SLC19A2 and SLC19A3) to identify genetic variants in DNA extracted from blood samples. Sanger sequencing is done by Polymerase Chain Reaction (PCR) instrumentation and the unit of measure is single nucleotide polymorphism (SNPs) detected. | As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles)] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT03263442 -
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT05663164 -
Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS)
|
N/A | |
Withdrawn |
NCT03122678 -
Thiamine Supplementation in Patients With Septic Shock
|
Phase 1 | |
Completed |
NCT04641104 -
The Thiamine Administration After Cardiac Surgery Trial
|
Phase 4 | |
Recruiting |
NCT06298344 -
The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease
|
Early Phase 1 | |
Completed |
NCT03626337 -
Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR
|
||
Completed |
NCT05390086 -
Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders
|
||
Recruiting |
NCT05480943 -
Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
|
||
Active, not recruiting |
NCT04453761 -
Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
|
Phase 4 | |
Completed |
NCT03554668 -
Systemic Inflammatory Response: Thiamine and Magnesium Status (Sir TaM Study)
|
||
Completed |
NCT01524315 -
Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery
|
Phase 4 | |
Completed |
NCT03616288 -
Trial of Thiamine Supplementation in Cambodia
|
N/A | |
Completed |
NCT02464865 -
Thiamin Deficiency in Obese Thai Children
|
Phase 4 | |
Completed |
NCT03228030 -
Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial
|
Phase 1 |